Lipopolysaccharide, immune activation, and liver abnormalities in HIV/hepatitis B virus (HBV)-coinfected individuals receiving HBV-active combination antiretroviral therapy

Megan Crane, Anchalee Avihingsanon, Reena Rajasuriar, Pushparaj Velayudham, David Iser, Ajantha Solomon, Baotuti Sebolao, Andrew Tran, Tim Spelman, Gail V Matthews, Paul Urquhart Cameron, Pisit Tangkijvanich, Gregory J Dore, Kiat Ruxrungtham, Sharon Ruth Lewin

Research output: Contribution to journalArticleResearchpeer-review

16 Citations (Scopus)

Abstract

We investigated the relationship between microbial translocation, immune activation, and liver disease in human immunodeficiency virus (HIV)/hepatitis B virus (HBV) coinfection. Lipopolysaccharide (LPS), soluble CD14, CXCL10, and CCL-2 levels were elevated in patients with HIV/HBV coinfection. Levels of LPS, soluble CD14, and CCL-2 declined following receipt of HBV-active combination antiretroviral therapy (cART), but the CXCL10 level remained elevated. No markers were associated with liver disease severity on liver biopsy (n = 96), but CXCL10, interleukin 6 (IL-6), interleukin 10 (IL-10), tumor necrosis factor a, and interferon ? (IFN-?) were all associated with elevated liver enzyme levels during receipt of HBV-active cART. Stimulation of hepatocyte cell lines in vitro with IFN-? and LPS induced a profound synergistic increase in the production of CXCL10. LPS may contribute to liver disease via stimulating persistent production of CXCL10.
Original languageEnglish
Pages (from-to)745 - 751
Number of pages7
JournalJournal of Infectious Diseases
Volume210
Issue number5
DOIs
Publication statusPublished - 2014

Cite this

Crane, Megan ; Avihingsanon, Anchalee ; Rajasuriar, Reena ; Velayudham, Pushparaj ; Iser, David ; Solomon, Ajantha ; Sebolao, Baotuti ; Tran, Andrew ; Spelman, Tim ; Matthews, Gail V ; Cameron, Paul Urquhart ; Tangkijvanich, Pisit ; Dore, Gregory J ; Ruxrungtham, Kiat ; Lewin, Sharon Ruth. / Lipopolysaccharide, immune activation, and liver abnormalities in HIV/hepatitis B virus (HBV)-coinfected individuals receiving HBV-active combination antiretroviral therapy. In: Journal of Infectious Diseases. 2014 ; Vol. 210, No. 5. pp. 745 - 751.
@article{bdb024fe72ae4fc18870be23c720d12f,
title = "Lipopolysaccharide, immune activation, and liver abnormalities in HIV/hepatitis B virus (HBV)-coinfected individuals receiving HBV-active combination antiretroviral therapy",
abstract = "We investigated the relationship between microbial translocation, immune activation, and liver disease in human immunodeficiency virus (HIV)/hepatitis B virus (HBV) coinfection. Lipopolysaccharide (LPS), soluble CD14, CXCL10, and CCL-2 levels were elevated in patients with HIV/HBV coinfection. Levels of LPS, soluble CD14, and CCL-2 declined following receipt of HBV-active combination antiretroviral therapy (cART), but the CXCL10 level remained elevated. No markers were associated with liver disease severity on liver biopsy (n = 96), but CXCL10, interleukin 6 (IL-6), interleukin 10 (IL-10), tumor necrosis factor a, and interferon ? (IFN-?) were all associated with elevated liver enzyme levels during receipt of HBV-active cART. Stimulation of hepatocyte cell lines in vitro with IFN-? and LPS induced a profound synergistic increase in the production of CXCL10. LPS may contribute to liver disease via stimulating persistent production of CXCL10.",
author = "Megan Crane and Anchalee Avihingsanon and Reena Rajasuriar and Pushparaj Velayudham and David Iser and Ajantha Solomon and Baotuti Sebolao and Andrew Tran and Tim Spelman and Matthews, {Gail V} and Cameron, {Paul Urquhart} and Pisit Tangkijvanich and Dore, {Gregory J} and Kiat Ruxrungtham and Lewin, {Sharon Ruth}",
year = "2014",
doi = "10.1093/infdis/jiu119",
language = "English",
volume = "210",
pages = "745 -- 751",
journal = "Journal of Infectious Diseases",
issn = "0022-1899",
publisher = "Oxford University Press",
number = "5",

}

Crane, M, Avihingsanon, A, Rajasuriar, R, Velayudham, P, Iser, D, Solomon, A, Sebolao, B, Tran, A, Spelman, T, Matthews, GV, Cameron, PU, Tangkijvanich, P, Dore, GJ, Ruxrungtham, K & Lewin, SR 2014, 'Lipopolysaccharide, immune activation, and liver abnormalities in HIV/hepatitis B virus (HBV)-coinfected individuals receiving HBV-active combination antiretroviral therapy', Journal of Infectious Diseases, vol. 210, no. 5, pp. 745 - 751. https://doi.org/10.1093/infdis/jiu119

Lipopolysaccharide, immune activation, and liver abnormalities in HIV/hepatitis B virus (HBV)-coinfected individuals receiving HBV-active combination antiretroviral therapy. / Crane, Megan; Avihingsanon, Anchalee; Rajasuriar, Reena; Velayudham, Pushparaj; Iser, David; Solomon, Ajantha; Sebolao, Baotuti; Tran, Andrew; Spelman, Tim; Matthews, Gail V; Cameron, Paul Urquhart; Tangkijvanich, Pisit; Dore, Gregory J; Ruxrungtham, Kiat; Lewin, Sharon Ruth.

In: Journal of Infectious Diseases, Vol. 210, No. 5, 2014, p. 745 - 751.

Research output: Contribution to journalArticleResearchpeer-review

TY - JOUR

T1 - Lipopolysaccharide, immune activation, and liver abnormalities in HIV/hepatitis B virus (HBV)-coinfected individuals receiving HBV-active combination antiretroviral therapy

AU - Crane, Megan

AU - Avihingsanon, Anchalee

AU - Rajasuriar, Reena

AU - Velayudham, Pushparaj

AU - Iser, David

AU - Solomon, Ajantha

AU - Sebolao, Baotuti

AU - Tran, Andrew

AU - Spelman, Tim

AU - Matthews, Gail V

AU - Cameron, Paul Urquhart

AU - Tangkijvanich, Pisit

AU - Dore, Gregory J

AU - Ruxrungtham, Kiat

AU - Lewin, Sharon Ruth

PY - 2014

Y1 - 2014

N2 - We investigated the relationship between microbial translocation, immune activation, and liver disease in human immunodeficiency virus (HIV)/hepatitis B virus (HBV) coinfection. Lipopolysaccharide (LPS), soluble CD14, CXCL10, and CCL-2 levels were elevated in patients with HIV/HBV coinfection. Levels of LPS, soluble CD14, and CCL-2 declined following receipt of HBV-active combination antiretroviral therapy (cART), but the CXCL10 level remained elevated. No markers were associated with liver disease severity on liver biopsy (n = 96), but CXCL10, interleukin 6 (IL-6), interleukin 10 (IL-10), tumor necrosis factor a, and interferon ? (IFN-?) were all associated with elevated liver enzyme levels during receipt of HBV-active cART. Stimulation of hepatocyte cell lines in vitro with IFN-? and LPS induced a profound synergistic increase in the production of CXCL10. LPS may contribute to liver disease via stimulating persistent production of CXCL10.

AB - We investigated the relationship between microbial translocation, immune activation, and liver disease in human immunodeficiency virus (HIV)/hepatitis B virus (HBV) coinfection. Lipopolysaccharide (LPS), soluble CD14, CXCL10, and CCL-2 levels were elevated in patients with HIV/HBV coinfection. Levels of LPS, soluble CD14, and CCL-2 declined following receipt of HBV-active combination antiretroviral therapy (cART), but the CXCL10 level remained elevated. No markers were associated with liver disease severity on liver biopsy (n = 96), but CXCL10, interleukin 6 (IL-6), interleukin 10 (IL-10), tumor necrosis factor a, and interferon ? (IFN-?) were all associated with elevated liver enzyme levels during receipt of HBV-active cART. Stimulation of hepatocyte cell lines in vitro with IFN-? and LPS induced a profound synergistic increase in the production of CXCL10. LPS may contribute to liver disease via stimulating persistent production of CXCL10.

UR - http://jid.oxfordjournals.org/content/210/5/745.full.pdf

U2 - 10.1093/infdis/jiu119

DO - 10.1093/infdis/jiu119

M3 - Article

VL - 210

SP - 745

EP - 751

JO - Journal of Infectious Diseases

JF - Journal of Infectious Diseases

SN - 0022-1899

IS - 5

ER -